Answers are grounded in this paper and cite their sources.
In recent years, the gut microbiota has emerged as an important regulator of metabolic health and a potential therapeutic target for metabolic disorders, including obesity and diabetes. Among the diverse metabolites and bioactive compounds produced by gut bacteria, bacterial exopolysaccharides (EPS) have attracted increasing attention. This is largely due to their structural similarity to dietary fiber and their potential prebiotic effects on the intestinal environment. Accumulating evidence suggests that bacterial EPS can modulate host immune responses and glucose metabolism, thereby maintaining metabolic homeostasis through interactions between the gut microbiota and the host. Understanding the molecular and physiological mechanisms underlying these effects may provide new insights into the role of bacterial EPS in host metabolic regulation. This may aid in revealing their potential as novel targets for the prevention and treatment of metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: